External Validation of Ten Prediction Models for 30-day Mortality Following Hip Fracture
PROTECT
1 other identifier
observational
3,500
1 country
1
Brief Summary
This study aims to externally validate ten existing prediction models with a low risk of bias for 30-day mortality following hip fracture. Data will be collected from the Dutch Hip Fracture Audit (DHFA) and supplemented with structured and unstructured data extracted through text mining using CTcue. Approximately 35 clinical variables will be used, including factors consistently associated with short-term mortality. The primary outcome is all-cause mortality within 30 days after hip fracture. Predictive performance will be assessed through discrimination (AUC), explained variance (R²), and calibration analysis. Clinical usefulness will be evaluated using Net Benefit and Decision Curve Analysis. This study seeks to identify models with strong predictive performance and practical applicability to support shared decision-making between clinicians and patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2024
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2024
CompletedFirst Submitted
Initial submission to the registry
April 29, 2025
CompletedFirst Posted
Study publicly available on registry
May 7, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2026
CompletedNovember 17, 2025
April 1, 2025
1.6 years
April 29, 2025
November 14, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
30-day mortality
Occurrence of death from any cause within 30 days following hip fracture diagnosis or hospital admission. Mortality status (yes/no) will be determined based on hospital records and confirmed via the Dutch national population registry (Basisregistratie Personen, BRP).
30 days post-fracture
Secondary Outcomes (1)
Discriminative Ability (AUC)
30 days post-fracture
Other Outcomes (4)
Explained Variance (R²)
30 days post-fracture
Calibration
30 days post-fracture
Comparison of Model Discrimination (DeLong Test)
30 days post-fracture
- +1 more other outcomes
Eligibility Criteria
The study population consists of patients who underwent surgery for a hip fracture at OLVG between January 1, 2016, and June 6, 2024, including procedures with hemiarthroplasty or internal fixation. The average age of the study population is approximately 80 years. The cohort is inclusive due to the broad inclusion and minimal exclusion criteria, and data collection is based on an anonymous search strategy. This real-world population includes individuals who might not typically participate in randomized clinical trials, enhancing the generalizability of the results. In addition, the study identifies patients admitted with a hip fracture who did not undergo surgery during the same period, allowing for a comparison of demographic and clinical characteristics between operated and non-operated patients.
You may qualify if:
- Patients admitted to OLVG between January 1, 2016, and March 1, 2024, with a diagnosis of hip fracture; and/or.
- Patients who underwent surgery at OLVG between January 1, 2016, and March 1, 2024, with an indication of hip fracture; and.
- Availability of independent predictor variables for at least one of the selected prediction models in the medical record.
You may not qualify if:
- Patients with unknown 30-day follow-up mortality status.
- Patients with periprosthetic fractures (fractures around an existing hip prosthesis) at the time of presentation.
- Patients aged under 18 years at the time of hip fracture.
- Patients who declined the use of their medical data for research purposes.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- JointResearchlead
Study Sites (1)
OLVG
Amsterdam, 1091AC, Netherlands
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Diederik H.R. Kempen, Dr.
OLVG
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 29, 2025
First Posted
May 7, 2025
Study Start
June 1, 2024
Primary Completion
December 31, 2025
Study Completion
June 1, 2026
Last Updated
November 17, 2025
Record last verified: 2025-04
Data Sharing
- IPD Sharing
- Will not share
Retrospective study using patient records without explicit consent for IPD sharing.